The Study of the Early Administration of Alendronate on Prevention of Bone Loss After Hip Fracture.

A Six Month Double-Blind, Placebo-Controlled Trial Followed by Six Month Open-Label Study of the Early Administration of Alendronate on Prevention of Bone Loss After Hip Fracture.

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00346190

Enrollment

Registered

2006-06-29

Start date

2003-01-31

Completion date

2007-04-30

Last updated

2007-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis

Brief summary

To determine whether administration of Alendronate early is more effective than late in the prevention of osteoporosis following a hip fracture

Interventions

DRUGAlendronate

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

55 Years to No maximum

Healthy volunteers

Inclusion criteria

Male and Female aged \> 55 Low trauma hip fracture up to 90 days Be willing to submit to periodic bone mineral density radiographic studies of the spine & 24 hr urine collection Written informed consent \-

Exclusion criteria

* Disorders known to affect bone metabolism Not taking bisphosphonates within last 6 months Drugs known to interfere with calcium metabolism within the lats 6 months prior to hip fracture serum calcium\> 2.65 mmol/L Treatment with any investigational drug within the last 30 days

Countries

Canada

Contacts

Primary ContactRichard Kremer, MD PhD

514-934-1934

Backup ContactGiselle Charrette, RN CONc

giselle.charrette@muhc.mcgill.ca514-934-1934

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026